ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

DMAC vs INDP // OPTIONS IMPLIED MOVE & PUT/CALL SKEW

DiaMedica Therapeutics Inc. (NASDAQ) VS. Indaptus Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: DMAC 2 — INDP 1
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (DMAC VS. INDP) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC DMAC INDP SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield -5.67% -2.89% -2.78 INDP /fcf-yield <GO>
Operating Margin — — — TIE /operating-margins <GO>
Net Profit Margin — — — TIE /net-margins <GO>
Revenue Growth (YoY) — — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 2/9 2/9 0.00 TIE /piotroski-score <GO>
Options Implied Move & Put/Call Skew ACTIVE — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 63.0 54.2 +8.83 DMAC /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $513.4M $513.0M $411.1K DMAC /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR DMAC REV INDP REV DMAC GROSS % INDP GROSS % DMAC FCF INDP FCF
FY 2025 $0 $0 — — -$29.1M -$14.8M
FY 2024 $0 $0 — — -$22.1M -$12.3M
FY 2023 $0 $0 — — -$18.7M -$13.4M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
DMAC // BETA —
INDP // BETA —